Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Gains from Sales and Divestitures (2016)

Historic Gains from Sales and Divestitures for Anaptysbio (ANAB) over the last 3 years, with Q4 2016 value amounting to $1000.0.

  • Anaptysbio's Gains from Sales and Divestitures fell 6666.67% to $1000.0 in Q4 2016 from the same period last year, while for Dec 2016 it was $1000.0, marking a year-over-year decrease of 6666.67%. This contributed to the annual value of $1000.0 for FY2016, which is 6666.67% down from last year.
  • Per Anaptysbio's latest filing, its Gains from Sales and Divestitures stood at $1000.0 for Q4 2016, which was down 6666.67% from $3000.0 recorded in Q4 2015.
  • Anaptysbio's Gains from Sales and Divestitures' 5-year high stood at $3000.0 during Q4 2014, with a 5-year trough of $1000.0 in Q4 2016.
  • Over the past 3 years, Anaptysbio's median Gains from Sales and Divestitures value was $3000.0 (recorded in 2014), while the average stood at $2333.3.
  • In the last 5 years, Anaptysbio's Gains from Sales and Divestitures changed by 0.0% in 2015 and then plummeted by 6666.67% in 2016.
  • Quarter analysis of 3 years shows Anaptysbio's Gains from Sales and Divestitures stood at $3000.0 in 2014, then changed by 0.0% to $3000.0 in 2015, then plummeted by 66.67% to $1000.0 in 2016.
  • Its Gains from Sales and Divestitures stands at $1000.0 for Q4 2016, versus $3000.0 for Q4 2015 and $3000.0 for Q4 2014.